Page last updated: 2024-12-08

1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)-1-nitrosourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

The compound you're describing is **1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)-1-nitrosourea**. It's a bit of a mouthful, and you'll often see it referred to by its shorter name, **CCNU**.

**CCNU is an alkylating agent, a type of chemotherapy drug.** Here's a breakdown of its components and their significance:

* **1-Nitrosourea:** This is the core functional group responsible for the drug's cytotoxic (cell-killing) activity. It releases a highly reactive nitrogen-containing species that can damage DNA within cancer cells.
* **1-(2-chloroethyl):** This portion of the molecule is also involved in the alkylating process. It can react with DNA, creating cross-links that interfere with its function.
* **3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl):** This part of the molecule, sometimes referred to as the TEMPO group, is a stable free radical. This allows for CCNU to be studied with techniques like electron paramagnetic resonance (EPR) spectroscopy.

**CCNU's Importance in Research:**

CCNU has been historically important in cancer research, particularly in the treatment of **brain tumors**. However, it is **no longer widely used clinically** due to its severe side effects.

Here's why it remains relevant in research:

* **Understanding Cancer Biology:** CCNU has been instrumental in understanding how alkylating agents work at the molecular level, providing insight into the mechanisms of DNA damage and repair.
* **Development of New Drugs:** The structure of CCNU has served as a basis for the development of newer and safer alkylating agents, such as lomustine, which have fewer side effects.
* **Probing Cell Processes:** The TEMPO group makes CCNU a useful tool for studying various biological processes, including:
* The delivery and uptake of drugs into cells.
* The mechanisms of drug resistance.
* The dynamics of free radical reactions in living systems.

**Overall, while CCNU is not a standard treatment for cancer today, it remains an important research tool for studying cancer biology and for developing new and more effective anti-cancer agents.**

1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)-1-nitrosourea: has more antineoplastic activity & less toxicity than CCNU; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID134164
MeSH IDM0131160

Synonyms (9)

Synonym
unii-w77mz42gar
slnu
slcnu
1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)-1-nitrosourea
nu 2
brn 5985884
83144-41-6
DTXSID401003160
[4-({[(2-chloroethyl)(nitroso)amino](hydroxy)methylidene}amino)-2,2,6,6-tetramethylpiperidin-1-yl]oxidanyl
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]